Download PDF
Z Gastroenterol 2005; 43(2): 219-225
DOI: 10.1055/s-2004-813928
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Hereditäre gastrointestinale Neoplasien

Hereditary Gastrointestinal NeoplasiasV. Fendrich1 , D. K. Bartsch1
  • 1Klinik für Visceral-, Thorax- und Gefäßchirurgie der Philipps-Universität Marburg
Further Information

Publication History

Publication Date:
07 February 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hereditäre Neoplasien sind für etwa 5 % der gastrointestinalen Tumorerkrankungen verantwortlich. Die Identifizierung ursächlicher Genmutationen eröffnet eine neue Dimension in der Prädiktion und Prävention dieser Tumorerkrankungen. In dieser Übersichtsarbeit werden die aktuellen Erkenntnisse zu Epidemiologie, klinischem Erscheinungsbild, Pathologie und molekulargenetischem Hintergrund sowie Diagnostik und Therapie der familiären adenomatösen Polyposis (FAP), des hereditären nichtpolypösen Kolonkarzinoms (HNPCC), des hereditären diffusen Magenkarzinoms (HDGC) und des familiären Pankreaskarzinoms (FPC) dargestellt und diskutiert.

Abstract

Hereditary gastrointestinal tumors account for approximately 5 % of the overall gastrointestinal cancer burden. The identification of underlying gene mutations opened up a new dimension regarding prediction and prevention of these hereditary tumors. In this review the current knowledge of epidemiology, clinical findings, pathology and genetic background, surveillance and treatment options of familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer syndrome (HNPCC), hereditary diffuse gastric cancer (HDGC) and familial pancreatic cancer (FPC) are described and discussed.

Schlüsselwörter

Hereditäre gastrointestinale Neoplasien - FAP - HNPCC - familiäres Magenkarzinom - familiäres Pankreaskarzinom

Key words

Hereditary gastrointestinal neoplasias - familial adenomatous polyposis (FAP) - hereditary non-polyposis colorectal cancer syndrome (HNPCC) - hereditary diffuse gastric cancer (HDGC) - familial pancreatic cancer (FPC)

Literatur

  • 1 Bundesärztekammer . Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen.  Dtsch Arztebl. 1998;  56 B1120-1127
    PubMedGoogle Scholar
  • 2 Watanabe H, Enjoji M, Yao T. et al . Gastric lesions in familial adenomatosis coli: their incidence and histological analysis.  Hum Pathol. 1978;  9 269-283
    PubMedGoogle Scholar
  • 3 Bodmer W F, Bailey C J, Bodmer J. et al . Localization of the gene for familial adenomatous polyposis on chromosome 5.  Nature. 1987;  328 614-616
    CrossrefPubMedGoogle Scholar
  • 4 Morin P J. Beta-catenin signalling and cancer.  Bioessays. 1999;  21 1021-1030
    PubMedGoogle Scholar
  • 5 Friedl W, Caspari R, Sengteller M. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families.  Gut. 2001;  48 515-521
    PubMedGoogle Scholar
  • 6 Spirio L N, Olschwang S, Groden J. Alleles of the APC gene an attenuated form of familial polyposis.  Cell. 1993;  56 955-958
    PubMedGoogle Scholar
  • 7 Bertario L, Russo A, Sala P. et al . Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis.  Int J Cancer. 2001;  95 102-107
    CrossrefPubMedGoogle Scholar
  • 8 Vasen H FA, Bülow S, Group a TCLP. Guidelines for the surveillance and management of familial adenomatous polyposis (FAP): a worldwide survey among 41 registries.  Colorectal Dis. 1999;  1 214-221
    CrossrefPubMedGoogle Scholar
  • 9 Johnson J C, DiSario J A, Grady W M. Surveillance and treatment of periampullary and duodenal adenomas in familial adenomatous polyposis.  Curr Treat Poptions Gastroenterol. 2004;  7 79-89
    PubMedGoogle Scholar
  • 10 Möslein G, Pistorius S, Saeger H D. et al . Preventive surgery for colon cancer in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer syndrome.  Langenbecks Arch Surg. 2003;  389 9-16
    PubMedGoogle Scholar
  • 11 de Vos t ot Nederveen Cappel WH, Järvinen H J, Björk J. et al . Worlwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis.  Br J Surg. 2003;  90 705-710
    CrossrefPubMedGoogle Scholar
  • 12 Jänne P A, Mayer R J. Chemoprevention of colorectal cancer.  N Engl J Med. 2000;  342 1960-1965
    CrossrefPubMedGoogle Scholar
  • 13 Steinbach G, Lynch P M, Phillips R K. et al . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med. 2000;  342 1946-1952
    CrossrefPubMedGoogle Scholar
  • 14 Higuchi T, Iwama T, Yoshinaga K. et al . A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cylooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.  Clin Cancer Res. 2003;  9 4756-4760
    PubMedGoogle Scholar
  • 15 Schulmann K, Mangold E, Schmiegel W. et al . Wirksamkeit der Krebsfrüherkennung beim hereditären kolorektalen Karzinom ohne Polyposis.  Dtsch Arztebl. 2004;  101 A506-512
    PubMedGoogle Scholar
  • 16 Fishel R, Kolodner R D. Identification of mismatch repair genes and their role in the development of cancer.  Curr Opin Genet Dev. 1995;  5 382-395
    CrossrefPubMedGoogle Scholar
  • 17 Lynch H T, Voorhees G J, Lanspa S J. et al . Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study.  Br J Cancer. 1985;  52 271-273
    CrossrefPubMedGoogle Scholar
  • 18 Vasen H F, Mecklin J P, Khan P. et al . The International Collaborative group on Hereditary Nonpolyposis Colorectal Cancer.  Dis Colon Rectum. 1991;  34 424-425
    PubMedGoogle Scholar
  • 19 Vasen H F, Watson P, Mecklin J P. et al . New clinical criteria for hereditary nonpolyposis colorectal cancer proposed by the International Collaborative group on HNPCC.  Gastroenterology. 1999;  116 1453-1456
    PubMedGoogle Scholar
  • 20 Rodriguez-Bigas M A, Boland C R, Hamilton S R. A National Cancer Institute workshop on HNPCC syndrome: meeting highlights and Bethesda guidelines.  J Natl Cancer Inst. 1997;  88 1317-1319
    PubMedGoogle Scholar
  • 21 Umar A, Boland C R, Terdiman J P. et al . Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.  J Natl Cancer Inst. 2004;  96 261-268
    CrossrefPubMedGoogle Scholar
  • 22 Lawes D A, SenGupta S B, Boulos P B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer.  Eur J Surg Oncol. 2003;  29 201
    CrossrefPubMedGoogle Scholar
  • 23 Järvinen H J, Aarnio M, Mustonen H. et al . Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.  Gastroenterology. 2000;  118 829-834
    CrossrefPubMedGoogle Scholar
  • 24 Vasen H F, Taal B G, Nagengast F M. et al . Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families.  Eur J Cancer. 1995;  31A 1145-1148
    PubMedGoogle Scholar
  • 25 Schmiegel W, Adler G, Frühmorgen P. et al . Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen.  Z Gastroenterol. 2000;  38 49-75
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Dunlop M G, Farrington S M, Carothers A D. et al . Cancer risk associated with germline DNA mismatch-repair-gene mutation.  Hum Mol Genet. 1997;  6 105-110
    CrossrefPubMedGoogle Scholar
  • 27 Yu H JA, Lin K M, Ota D M. et al . Hereditary nonpolyposis colorectal cancer: preventive management.  Cancer Treat Rev. 2003;  29 461-470
    CrossrefPubMedGoogle Scholar
  • 28 Syngal S, Weeks J C, Schrag D. et al . Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations.  Ann Intern Med. 1998;  129 787-796
    CrossrefPubMedGoogle Scholar
  • 29 Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes.  Cancer. 1999;  86 2551-2563
    CrossrefPubMedGoogle Scholar
  • 30 Oliveira C, Bordin M C, Grehan N. et al . Screening E-Cadherin in gastric cancer families reveals Germline mutations only in hereditary diffuse gastric cancer kindred.  Human Mutation. 2002;  19 510-517
    CrossrefPubMedGoogle Scholar
  • 31 Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice.  Ann Oncol. 2003;  14 1705-1713
    CrossrefPubMedGoogle Scholar
  • 32 Caldas C, Carneiro F, Lynch H AT. et al . Familial gastric cancer: overview and guidelines for management.  J Med Genet. 1999;  36 873-880
    PubMedGoogle Scholar
  • 33 Guilford P, Hopkins J, Harraway J. E-cadherin Germline mutations in familial gastric cancer.  Nature. 1998;  392 402-405
    CrossrefPubMedGoogle Scholar
  • 34 Handschuh G, Candidus S, Luber B. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility.  Oncogene. 1999;  18 4301-4312
    CrossrefPubMedGoogle Scholar
  • 35 Schwarz A. Preventive gastrectomy in patients with gastric cancer risk due to genetic alterations of the E-cadherin gene defect.  Langenbecks Arch Surg. 2003;  388 27-32
    PubMedGoogle Scholar
  • 36 Huntsman D, Carneiro F, Lewis F. et al . Prophylactic gastrectomy in patients with deleterious E-cadherin gene mutation.  Gastroenterol Clin Biol. 2001;  25 931-932
    PubMedGoogle Scholar
  • 37 Bartsch D K, Rieder H. Familial pancreatic cancer: an update.  Fam Cancer. 2004;  3 69-74
    PubMedGoogle Scholar
  • 38 Tersmette A C, Petersen G M, Offerhaus G J. et al . Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.  Clin Cancer Res. 2001;  7 738-744
    PubMedGoogle Scholar
  • 39 Rieder H, Sina-Frey M, Ziegler A. et al . German National Case Collection of Familial Pancreatic Cancer-Clinical Genetic Analysis of the First 21 Families.  Onkologie. 2002;  25 262-266
    CrossrefPubMedGoogle Scholar
  • 40 Rulyak S J, Brentnall T A, Lynch H T. et al . Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.  Cancer. 2003;  98 798-804
    CrossrefPubMedGoogle Scholar
  • 41 Murphy K M, Brune K A, Griffin C. et al . Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17 %.  Cancer Res. 2002;  62 3789-3793
    PubMedGoogle Scholar
  • 42 Hahn S A, Greenhalf W, Ellis I. et al . BRCA2 germline mutations in familial pancreatic cancer.  J Natl Cancer Inst. 2003;  95 214-221
    CrossrefPubMedGoogle Scholar
  • 43 Brentnall T A, Bronner M P, Byrd D R. et al . Early diagnosis and treatment of pancreatic dysplasia in patients with family history of pancreatic cancer.  Ann Intern Med. 1999;  131 247-255
    PubMedGoogle Scholar
  • 44 Bartsch D K, Sina-Frey M, Ziegler A. et al . Update of familial pancreatic cancer in Germany.  Pancreatology. 2001;  1 510-516
    PubMedGoogle Scholar
  • 45 Rulyak S J, Brentnall T A. Inherited pancreatic cancer: surveillance and treatment strategies for affected families.  Pancreatology. 2001;  1 1477-1485
    PubMedGoogle Scholar

PD Dr. Detlef K. Bartsch

Klinik für Visceral-, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg

Baldingerstraße

35043 Marburg

Phone: 064 21/2 86-6 25 72

Fax: 064 21/2 86 89 95

Email: bartsch@mailer.uni-marburg.de